| Abstract |
Objective: To observe the clinical efficacy and efficacy of mirtazapine and citalopram in the treatment of sleep disorders in patients with depression. Methods: From January 2017 to January 2019, 60 patients with depression and sleep disorders admitted to our hospital were randomly divided into 2 groups, 30 cases each. The control group was treated with escitalopram oxalate, and the observation group was treated based on this combined with mirtazapine. Comparison of PSQI (Pittsburgh Sleep Quality Index), MADRS (Montgomery Depression Rating Scale), and HAMD-17 (Hamilton Depression Scale 17) scores, clinical outcomes, adverse reactions, and quality of life (SF- before and after treatment) 36 scale) score. RESULTS: There were no significant differences in the scores of PSQI, MADRS, HAMD-17, etc. before treatment (P>0.05). However, the improvement of the observation group was better than that of the control group after treatment, and there was statistical difference between them. P < 0.05). In the treatment efficiency, the control group was 73.33% overall, while the observation group was 96.67% overall. There was a statistical difference between the two groups (P<0.05). In terms of adverse reactions, the incidence of the control group was 13.33%, and the incidence of the observation group was 10.0%. There was a statistically significant difference between the two groups (P<0.05). In terms of quality of life, there were statistical differences in the scores of social, physiological, physical functions, and emotional functions between the two groups (P<0.05). Conclusion: The efficacy of mirtazapine and citalopram in the treatment of sleep disorders in patients with depression is significant, which can significantly improve the sleep disorders and depressive symptoms of patients with less adverse reactions, higher safety, and improve the quality of life of patients, so it is worthy of clinical Promotion and application.
|